Coronary artery disease in giant cell arteritis: A systematic review and meta-analysis

Seminars in Arthritis and Rheumatism

Volumn 44, Issue 5, 2015, Pages 586-591

  Ungprasert, Patompong ^a   Koster, Matthew J ^a   Warrington, Kenneth J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Coronary artery disease; Epidemiology; Giant cell arteritis; Meta analysis

Indexed keywords

ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; FOLLOW UP; GIANT CELL ARTERITIS; HAZARD RATIO; HUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; COMPLICATION; INCIDENCE; META ANALYSIS;

CORONARY ARTERY DISEASE; GIANT CELL ARTERITIS; HUMANS; INCIDENCE;

EID: 84926339762     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2014.10.010     Document Type: Article

References (41)

1. Frostegard J. Atherosclerosis in patients with autoimmune disorders. Arterioscler Thromb Vasc Biol 2005, 25:1776-1785.
2. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
3. Montecucco F., Mach F. Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology (Oxford) 2009, 48:11-22.
4. Rho Y.H., Chung C.P., Oeser A., Solus J.F., Gebretsadik T., Shintani A., et al. Interaction between oxidative stress and high-density lipoprotein cholesterol is associated with severity of coronary artery calcification in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2010, 62:1473-1480.
5. Niessner A., Sato K., Chaikof E.L., Colmegna I., Goronzy J.J., Weyand C.M. Pathogen-sensing plasmacytoid dendritic cells stimulate cytotoxic T-cell function in atherosclerotic plaque through interferon-alpha. Circulation 2006, 114:2482-2489.
6. Hansen S., Lassig G., Pistrosch E., Passauer J. Endothelial dysfunction in young patients with long-term rheumatoid arthritis and low disease activity. Atherosclerosis 2003, 170:177-180.
7. Xu J., Lupu F., Esmon C.T. Inflammation, innate immunity and blood coagulation. Hamostaseologie 2010, 30:8-9.
8. Esmon C.T. The interactions between inflammation and coagulation. Br J Haematol 2005, 131:417-430.
9. Maradit-Kremers H., Nicola P.J., Crowson C.S., Ballman K.V., Gabreil S.E. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005, 52:722-732.
10. Bessant R., Hingorani, Patel L., MacGregor A., Isenberg D.A., Rahman A. Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. Rheumatology (Oxford) 2004, 43:924-929.
11. Ungprasert P., Charoenpong P., Ratanasrimetha P., Thongprayoon C., Cheungpasitporn W., Suksaranjit P. Risk of coronary artery disease in patients with systemic sclerosis: a systematic review and meta-analysis. Clin Rheumatol 2014, 33:1099-1104.
12. Ungprasert P., Suksaranjit P., Spanuchart I., Leeaphorn N., Permpalung N. Risk of coronary artery disease in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis of observational studies. Semin Arthritis Rheum 2014, 44:63-67.
13. Salvarani C., Cantini F., Hunder G.G. Polymyalgia rheumatica and giant-cell arteritis. Lancet 2008, 372:234-245.
14. Gonzalez-Gay M.A., Vazquez-Rodriguez T.R., Lopez-Diaz M.J., Miranda-Filloy J.A., Gonzalez-Juanatey C., Martin J., et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 2009, 61:1454-1461.
15. Ray J.G., Mamdani M.M., Geerts W.H. Giant cell arteritis and cardiovascular disease in older adults. Heart 2005, 91:324-328.
16. Le Page L., Duhaut P., Seydoux D., Bosshard S., Ecochard R., Abbas F., et al. Incidence of cardiovascular events in giant cell arteritis: preliminary results of a prospective double cohort study (GRACG). Rev Med Interne 2006, 27:98-105.
17. Molloy ES, Kirchner HL, Murray PK, Hoffman GS, Langford CA. Cardio-vascular outcomes in giant cell arteritis. Presented at the American College of Rheumatology Annual Scientific Meeting, 6-11 November 2007, Boston, Massachusetts. [Abstract no. 1235].
18. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010, 25:603-605.
19. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trial 1986, 7:177-188.
20. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. Br Med J 2003, 327:557-560.
21. Dunstan E., Lester S.L., Rischmueller M., Dodd T., Black R., Ahern M., et al. Epidemiology of biopsy-proven giant cell arteritis in South Australia. Intern Med J 2014, 44:32-39.
22. García-Martínez A., Arguis P., Prieto-González S., Espígol-Frigolé G., Alba M.A., Butjosa M., et al. Prospective long term follow-up of a cohort of patients with giant cell arteritis screened for aortic structural damage (aneurysm or dilatation). Ann Rheum Dis 2014, 73:1826-1832.
23. Souza A.W., Okamoto K.Y., Abrantes F., Schau B., Bacchiega A.B., et al. Giant cell arteritis: a multicenter observational study in Brazil. Clinics 2013, 68:317-322.
24. Kisza K., Murchison A.P., Dai Y., Bilyk J.R., Eagle R.C., Sergott R., et al. Giant cell arteritis incidence: analysis by season and year in mid-Atlantic United States. Clin Experiment Ophthalmol 2013, 41:577-581.
25. Espitia O., Néel A., Leux C., Connault J., Espitia-Thibault A., Ponge T., et al. Giant cell arteritis with or without aortitis at diagnosis. A retrospective study of 22 patients with longterm followup. J Rheumatol 2012, 39:2157-2162.
26. Abdul-Rahman A.M., Molteno A.C., Bevin T.H. The epidemiology of giant cell arteritis in Otago, New Zealand: a 9-year analysis. N Z Med J 2011, 124:44-52.
27. Singh S., Balakrishnan C., Mangat G., Samant R., Bambani M., Kalke S., et al. Giant cell arteritis in Mumbai. J Assoc Physicians India 2010, 58:372-374.
28. Aziz S., Al-Ansari A., Bankart J., McFadzean R. Clinical manifestations and laboratory tests in biopsy proven giant cell arteritis in Glasgow. Eur J Intern Med 2009, 20:e146.
29. Gonzalez-Gay M.A., Rubiera G., Pineiro A., Garcia-Porrua C., Pego-Reigosa R., Gonzalez-Juanatey C., et al. Ischemic heart disease in patients from northwest Spain with biopsy proven giant cell arteritis. A population based study. J Rheum 2005, 32:502-506.
30. Uddhammar A., Eriksson A.L., Nystrom L., Stenling R., Rantapaa-Dahlqvist S. Increased mortality due to cardiovascular disease in patients with giant cell arteritis in northern Sweden. J Rheum 2002, 29:737-742.
31. Machado E.B.V., Gabriel S.E., Beard C.M., Michet C.J., O'Fallon W.M., Ballard D.J. A population-based case-control study of temporal arteritis: evidence for an association between temporal arteritis and degenerative vascular disease. Int J Epidemiol 1989, 18:836-841.
32. Amiri N, Choi HK, Sayre EC, Shojania K, Avina-Zubieta JA. Risk of myocardial infarction in patients with giant cell arteritis: a population-based study. Presented at the American College of Rheumatology Annual Scientific Meeting, 25-30 October 2013, San Diego, California. [Abstract no. 1673].
33. Tomasson G., Peloquin C., Mohammad A., Love T.J., Zhang Y., Choi H.K. Risk for cardiovascular disease early and late after a diagnosis of giant-cell arteritis. A cohort study. Ann Intern Med 2014, 160:73-80.
34. Udayakumar P.D., Chandran A.K., Crowson C.S., Warrington K.J., Matteson E.L. Cardiovascular risk and acute coronary syndrome in giant cell arteritis: a population based retrospective cohort study. Arthritis Care Res (Hoboken) 2014, [Epub ahead of print]. 10.1002/acr.22416.
35. Matthews J.L., Gilbert D.N., Farris B.K., Siatkowski R.M. Prevalence of diabetes mellitus in biopsy-positive giant cell arteritis. J Neuroophthalmol 2012, 32:202-206.
36. Schmidt J., Kermani T.A., Muratore F., Crowson C.S., Matteson E.L., Warrington K.J. Statin use in giant cell arteritis: a retrospective study. J Rheumatol 2013, 40:910-915.
37. Gonzalez-Gay M.A., Pineiro A., Gomez-Gigirey A., Garcia-Porrua C., Pego-Reigosa R., Dierssen-Sotos T., et al. Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis. Medicine 2004, 83:342-347.
38. Gonzalez-Juanatey C., Lopez-Diaz M.J., Martin J., Llorca J., Gonzalez-Gay M.A. Atherosclerosis in patients with biopsy-proven giant cell arteritis. Arthritis Rheum 2007, 57:1481-1486.
39. Ly K.-H., Regent A., Tamby M.C., Mouthon L. Pathogenesis of giant cell arteritis: more than just an inflammatory condition?. Autoimmun Rev 2010, 9:635-645.
40. Casey J., Sturm C. Impaired response of lymphocytes from non-insulin dependent diabetics to staphage lysate and tetanus antigen. J Clin Microbiol 1982, 15:109-114.
41. Roman M.J., Shanker B.A., Davis A., Lockshin M.D., Sammaritano L., Simantov R., et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003, 349:2399-2406.